Summary
This 2024 multi-society clinical guideline synthesises evidence and expert consensus on perioperative cardiovascular management for patients undergoing noncardiac surgery. Developed collaboratively by major American cardiovascular and surgical societies (AHA, ACC, ACS, and others), the guideline provides recommendations on preoperative risk assessment, functional capacity evaluation, medical optimisation, and perioperative monitoring. The document updates prior guidance to reflect contemporary evidence on cardiovascular complications, medication management, and interventional strategies in the surgical period.
UK applicability
UK cardiovascular and anaesthetic practice may draw on these evidence-based recommendations, though implementation would need alignment with National Institute for Health and Care Excellence (NICE) guidance, NHS protocols, and British Cardiovascular Society standards. The guideline's risk stratification frameworks and pharmaceutical recommendations are broadly applicable to UK perioperative care, though medication availability and cost-effectiveness assessments may differ.
Key measures
Cardiovascular risk indices, perioperative adverse events, medication management protocols, imaging and screening recommendations
Outcomes reported
The guideline addresses cardiovascular assessment, risk stratification, and management strategies for patients undergoing noncardiac surgery. It synthesizes evidence on perioperative monitoring, pharmaceutical interventions, and risk reduction approaches.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.